ABSTRACT: Gastrointestinal (GI) tract leucine metabolism was measured in 6-to 9-mo-old lambs subjected to trickle infection with Trichostrongylus colubriformis larvae and in separate animals that were not infected. Animals prepared with a jejunal catheter and with indwelling catheters into the aorta and the portal-(PDV) and mesenteric-(MDV) drained viscera were infused simultaneously with [1-13 C] and [5,5, H 3 ] leucine to determine GI tract sequestration of leucine from arterial and luminal amino acid pools by tracer and tracee arteriovenous concentration differences. Leucine oxidative losses and net fluxes were also determined across the GI tract. Infection had no detectable effect
Introduction
Gastrointestinal (GI) helminths are a major cause of economic loss in farm animals. Depressed weight gain, alterations in body composition, depressed milk production, reductions in the quantity and quality of wool production, and reduced reproductive performance are all associated with the initial infection and the subsequent immune response periods of a range of nematodes that attack different regions of the postruminal tract (MacRae, 1993; Sykes, 1994; Coop and Holmes, 1996) .
One feature of GI tract helminthosis is endogenous protein loss. With Haemonchus sp. infection, as much To whom correspondence should be addressed (phone: +44 (0)1224 712751; fax: +44 (0)1224 715349; E-mail: j.macrae@rri.sari.ac.uk).
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on whole-body leucine flux, but it increased total GI tract leucine sequestration by 24% (P < .05) and GI tract oxidative losses of leucine by 22 to 41% (P < .01). Net PDV fluxes of leucine were decreased by 20 to 32% during the infection. The infection did not alter either the proportion of precursor leucine used by GI tract metabolism that was derived from the arterial leucine pool (.84 to .88) or the proportional sequestration of digesta-derived leucine during "first pass" absorptive metabolism (.12 to .18). These findings help to elucidate the metabolic basis for the reduced growth rates and nitrogen retention observed when animals are subjected to subclinical nematode infection.
as 10% of the circulating plasma volume can leak into the GI tract (Parkins and Holmes, 1989) . With Trichostrongylus sp., increased secretion of mucin and sloughing of epithelial cells into the GI tract can result in substantial (4 to 5 g N/d) increases in the endogenous N components that leave the small intestine (Poppi et al., 1986; Kimambo et al., 1988) . With Ostertagia sp., there is predominant mucosal hyperplasia (Armour and Ogbourne, 1982) , leading to increased serum gastrin concentrations (Sinder et al., 1988) . Thus, changes in the protein metabolism of the GI tract may be pivotal to the pathogenesis of helminthosis. Protein synthesis has been reported to increase substantially in the intestines of guinea pigs subjected to T. colubriformis infection (Symons and Jones, 1983) ; however, until recently, the lack of appropriate methodology has prevented the monitoring of protein turnover in the GI tract of infected farm animals.
The present study has used recently developed transorgan catheterization procedures, coupled with mass isotope tracer kinetics (MacRae et al., 1997) , to determine how subclinical T. colubriformis infection Table 1 . Identification of the number of collections achieved from the mesenteric-(MDV) and portal- (PDV) drained viscera in each lamb and the number of lambs used in the experiments MDV  PDV  MDV  PDV  MDV  PDV  MDV  PDV  no.  MDV  PDV  MDV  PDV  MDV  PDV   3,173  2  -----1  -3,182  -2  -1  --3,178  2  2  ------3,184  2  2  1  2  -2  2,892  2  2  ----2  2  8 0 9  2  2  2  1  --3,174  --2  2  ----3,180  2  2  -1  -2  2,702  --2  2  2  2  --29  2  1  -2  -2  3,177  ----2  2  1  0  8 0 7  -2  -2  --2,892  ------2  2  2 2  --2  2  1 alters amino acid use by the GI tract (as determined using tracer leucine) and the net availability of amino acid for metabolism by other tissues. Part of this study has been published in abstract form (Yu et al., , 1999 .
Experimental Procedures

Animals and Surgical Procedures
Experiments were conducted with Suffolk × Finn Dorset wether lambs (8 for control and 12 for infection; 30 to 40 kg live weight; 6 to 9 mo of age) that had been raised parasite-free from birth. The numbers of lambs used in the experiments and of collections of samples achieved are given in Table 1 . Each animal was prepared with a jejunal catheter for infusion of tracer and with indwelling catheters in the aorta, via the femoral artery, and portal (PDV) and mesenteric (MDV; n = 2) veins as described by MacRae et al. (1997) . All these catheters were established at least 3 to 4 wk before commencement of any experiments. A temporary catheter was also inserted into the external jugular vein, for infusion of tracer, at least 24 h before each infusion period when required.
Diet and Experimental Procedures
Following surgery, the animals were kept in recovery pens for 2 wk, during which time each received appropriate veterinary treatment of antibiotics and analgesics. They were then transferred to individual metabolism crates and fed a pelleted dried grass diet (DM content 944 g/kg; N content 25.6 g/kg DM) by means of frequent (hourly) feeders. All animals were housed in one building, but care was taken to keep the animals receiving parasite larvae well away from the control animals.
On recovery from surgery, lambs designated as "infected animals" were given, orally, a subclinical daily dose of 2,500 third-stage T. colubriformis larvae for the duration of the experiment (Poppi et al., 1986; Kimambo et al., 1988) . The larvae were supplied by the Moredun Research Institute, Midlothian, U.K. Previous studies using this level of T. colubriformis infection have indicated that there is a variable degree of inappetance associated with this infection. This can compromise the interpretation of data unless the corresponding measurements are made on control (noninfected) animals at equivalent intakes. In this study, these comparative measurements were obtained from noninfected animals given a range of intake (600 to 1,200 g/d; 10 d adaptation between each intake level) that covered the range consumed by infected animals (i.e., even where they exhibited inappetance). Regression analyses of data (variable vs intake) obtained from both the control and the infected groups were then used as the basis for evaluating whether the infection significantly altered any of the variables.
The main nutritional penalty in infected animals occurs from wk 4 to 14 of dosing (Poppi et al., 1986; Kimambo et al., 1988) . Thereafter, animals begin to exhibit resistance to the larvae challenge, and, by wk 18 of dosing, the differences between infected and noninfected animals are much smaller. In the present study, infected lambs were dosed daily for 20 wk, and measurements were taken over three experimental periods: 1) wk 5 to 7 of dosing (primary infection); 2) wk 11 to 13 of dosing (development of immunological resistance); and 3) wk 18 to 20 of dosing (recovery/immunologically competent). In an attempt to minimize loss of information due to catheter patency problems, animals used to obtain data for the first two experimental periods were surgically prepared prior to dosing with larvae, but a separate group of infected animals was dosed with larvae for 14 wk before surgery. These continued to receive daily doses of larvae during recovery from surgery and thereafter and were then used for collection of wk 18 to 20 data.
Fecal egg counts and whole blood eosinophil counts were monitored at regular intervals throughout the experimental period to characterize the different phases of the etiology of infection.
Tracer Infusion and Blood Sampling
Two separate tracers, L-[1-
13
C]leucine (99 atoms %) and L-[5,5,5-2 H 3 ]leucine (99 atoms %; both obtained from Masstrace, Woburn, MA) were used in the experiments.
During each experimental period of 3-wk duration, the two leucine tracers were infused on two occasions. Each time, one isotope was infused intravenously and the other was infused into the lumen of the jejunum; the site of administration of each isotope was reversed on the second occasion. Thus, during wk 5, 11, and 18 of dosing, a sterile solution containing 1 g of L-[1-
C]leucine and 9 g of NaCl/L was infused continuously into the jugular vein at a rate of 20 g/h over an 8-h period. At the same time, a similar dilution of L-[5,5,5-2 H 3 ]leucine was infused into the jejunum at a same rate and for the same time. Over the last 7 h of each infusion, sodium p-aminohippurate (pAH; 4 g/100 mL of sterile saline), a dye dilution marker used to determine blood flow rates by downstream dilution, and sodium heparin (4,750 IU) were infused into the proximal mesenteric catheter, also at a rate of 20 g/h. The heparin infusion allowed continuous withdrawal, by peristaltic pump, of aortal, mesenteric, and portal blood (10 mL/h into icecold syringes) between 5 and 8 h of the tracer infusion (MacRae et al., 1997) . In wk 7, 13, and 20 of dosing, the tracers infused into each site were reversed, but the sampling procedure remained the same.
Analyses
The hourly blood samples were analyzed immediately for pH, pO 2 , and pCO 2 with an ABL blood gas analyzer (Radiometer, Copenhagen, Denmark) and for packed cell volume (hematocrit). Mesenteric and portal vein blood flow rates were determined from the concentration of pAH in the respective hourly samples of blood (Harris et al., 1992) .
Duplicate samples of whole blood (.75 mL) were injected into evacuated 10-mL tubes containing .5 mL of frozen lactic acid and then analyzed for blood H 13 CO 3 enrichment with isotope ratio-mass spectrometry (IRMS; Sira-12 VG Isogas, Middewich, Cheshire, U.K.) as described by Read et al. (1984) .
Blood samples were also prepared for measurement of [ C]leucine (150 mol/mL). Each of these hemolyzed solutions was subdivided into three 2-mL aliquots and then stored at −20°C for further use. Stored blood samples were thawed slowly and prepared for GC-MS analysis, as previously described by Calder and Smith (1988) .
Samples of blood obtained before each tracer infusion were prepared similarly to provide natural abundance samples for IRMS and GCMS analyses.
Calculations
Rates of whole-body leucine flux (WBF; mmol/d) were calculated from the RE of the intravascular tracer in arterial blood collected over the latter 4 h of isotope infusion, with correction to accommodate infusion of radioinert quantities of the amino acid using the following equation:
where .99 is infusate enrichment, L jug,a is the RE of leucine in arterial blood, and I jug is jugular infusion rate (mol/min); 1.44 is a conversion ratio from minutes to day. These values can be converted to minimum estimates of whole-body protein flux (g/d) using the mean leucine concentration in body protein of sheep (66 g leucine /kg body protein; MacRae et al., 1993) . The fractional sequestration (S) of arterial leucine into the gastrointestinal tract (PDV) or small intestine (MDV) proteins and secretions was determined from the intravascular infusion data, using the equation as described by MacRae et al. (1997) :
where A l and V l are concentrations (M) of leucine in arterial and venous (portal or mesenteric) blood, respectively, and L jug,a and L jug,v are the [ Quantities of leucine (mmol/d) sequestrated into gastrointestinal tract proteins from arterial sources (Seqart ) were then calculated from the following equation:
where S is calculated, as in Eq.
[2] and BF is portal or mesenteric blood flow (L/min). Blood flow was estimated based on dilution of pAH, from the equation of [BF = pAH infusion rate/(pAH v − pAH a )], where (v) and (a) are pAH concentration in the mesenteric or portal and arterial blood, respectively.
Rates of sequestration of leucine into tissue proteins of the small intestine during absorption of digesta-derived leucine were calculated on the assumptions that leucine tracer infused into the jejunum, but not recovered at the portal vein, was sequestrated into gastrointestinal tract proteins; earlier studies (MacRae et al., 1997) had indicated that virtually all of the infused tracer disappears from the small intestine and that < 1.5% is detectable in ileal digesta. Recovery (R) of jejunal tracer at the portal vein was determined from the net portal flux, with correction made for the amount of tracer sequestrated from arterial blood during recirculation using the following equation:
× BF/I jej where P l is concentration (M) of leucine in portal blood; L jej,p and L jej,a are the RE of jejunally infused tracer in portal and arterial blood respectively; I jej is the jejunal infusion rate (mol/min) of that isotope, and S is calculated, as in Eq.
[2], using the data from the alternative leucine isotope simultaneously infused into the jugular vein. Quantities of leucine (mmol/d) sequestrated by small intestinal tissue proteins (Seq lum ) were then calculated from the following equation:
where App. Abs. Leu (mmol/d) is apparent absorption of leucine from the small intestine; Il. Endog. Leu is the calculated endogenous leucine leaving the small intestine in ileal digesta, and R is calculated as in Eq. [4] .
As reported previously (Poppi et al., 1986) , it is not possible to measure apparent absorption of amino acids from the small intestine of sheep infected with T. colubriformis, because presence of the infection disrupts the normal pattern of intestinal motility in the upper regions of the duodenum (Gregory et al., 1985) . As a result, samples of duodenal digesta are frequently severely contaminated with bile contents (bright green) and mucus, and their pH is considerably higher (range 2.8 to 6.5) than normal (range 2.1 to 2.8; see Poppi et al., 1986) . Therefore, in order to obtain estimates of Seq lum in the present studies, data for App. Abs. Leu and Il. Endog. Leu at different intakes in control and infected animals were calculated from regressions obtained in a separate study with animals given a diet containing similar N and ME (MacRae et al., 1997) . Although ileal flows of endogenous N are higher in infected animals, infection does not alter the true digestibility of digesta amino acids in the small intestine, as assessed from the recoveries of [ 
where V c and A c are concentrations (mM) of CO 2 in venous and arterial samples taken during the intravenous infusion of [ The absolute rate (mmol/d) of leucine oxidation during gastrointestinal tract metabolism of leucine sequestrated from the arterial leucine pool (Oxid art ) was calculated from this fractional oxidation and the rate of leucine sequestration (Eq. [3]) using venous α-KIC enrichment as the precursor:
where PF jug (L/min) is plasma flow, represented by BF × (1 − PCV), and K jug,v is α-KIC RE in venous (portal, or mesenteric) blood during the jugular infusion, assumed to provide the closest representation to intracellular leucine RE in the gastrointestinal tract tissues (Lobley et al., 1995) . The CO 2 concentrations were determined in plasma, whereas 13 CO 2 enrichments were determined in whole blood. Because enrichments of acid-liberated 13 CO 2 are similar in blood and plasma (Harris et al., 1992) , the latter have been used to correct for oxidative losses through plasma bicarbonate pools; however, blood flow data relating to the 13 CO 2 kinetics must be adjusted for PCV.
Oxidative losses associated with "first pass" absorption metabolism of digesta-derived leucine were calculated using the same principle during the infusion of [ 13 C]leucine tracer into the jejunum. Here it is necessary to correct for the amount of 13 CO 2 arising from the oxidation of "recirculated" arterial [ 13 C]leucine. Thus, the fractional rate of oxidation of digesta-derived leucine during absorption metabolism (Foxid l ) was calculated from the following equation:
where Foxid a is calculated from Eq. [6], I jej is the infusion rate of [ 13 C]leucine tracer into the jejunum, and R is calculated from Eq. [4] . Then the rate of leucine oxidation (mmol/d) by intestinal tissues during "first pass" absorption metabolism (Oxid lum ) was calculated as follows:
where Seq lum and Foxid l are calculated from Eq.
[5] and [8] . Net fluxes (mmol/d) of leucine across the gastrointestinal tract (PDV) were calculated with the following equation:
where P l and A l are concentrations (M) of leucine in portal and arterial blood and BF is portal blood flow.
Statistics
To determine rates of leucine sequestration, oxidative loss, and net flux across both the whole gastrointestinal tract (PDV) and small intestine only (MDV) simultaneously, all three sampling catheters (i.e., arterial, mesenteric, and portal) must be patent at the time of sampling. When the arterial catheter yielded blood, but either portal or mesenteric catheters did not, information on the whole gastrointestinal tract or small intestine only, but not both, was obtained (see Table 1 ).
All data obtained were used to develop the regression relationships (Table 2; Figure 1 ) of variable vs DM intake for control and for infected animals during the three periods of dosing (these regression analyses were used as a means of adjusting for substantial differences in feed intake). These relationships were significant (P < .001) (see Figure 1) . The effects of infection and period (week of dosing) of infection were estimated using REML (residual maximum likelihood) variance components analysis procedures in the Genstat statistical analysis package (Genstat, 1996) . The REML procedure allows the analysis of unbalanced data with multiple sources of error variation. In the present study, for these analyses the "fixed effects" were constant + parasite + period + intake, and variation due to animals and different infusion orders for the same animals were regarded as "random effects." When the component of variation due to differences between animals was negative, the two strata were combined to form a single stratum.
RESULTS
Appetite and Clinical Observations
As expected, feed intakes of infected sheep tended to decline from wk 5 to 14 of dosing with T. colubriformis larvae, but the degree of inappetance varied between animals. Intakes for individual animals ranged from 780 to 1,100 g/d during wk 5 to 7 of dosing (the first experimental period) and from 450 to 1,200 g/d during wk 11 to 13 (the second period). From wk 15 of dosing, this inappetance disappeared gradually, and, by wk 17, all dosed animals were consuming their total rations. To provide comparative regression data for the last period (wk 18 to 20 of dosing), these animals, surgically prepared during wk 15 of dosing, were allocated a range of intake between 600 and 1,200 g/d, the same range used for the noninfected (control) animals.
There were no clinical signs of infection in any of the animals receiving larvae at any stage of the experiment. However, infected animals had an erratic pattern of excretion of soft feces from wk 5 to 11 of dosing. Excretion of worm eggs in the feces and eosinophil levels in peripheral blood of infected sheep indicated the classical pattern of a primary infection followed by the development of immunological resistance. Fecal egg counts (eggs per gram of feces) peaked at wk 6 to 7 of dosing (901 ± 137.7 [mean ± SE], n = 9) and, thereafter, declined until none were detectable beyond wk 12 of dosing. Blood eosinophil levels increased from wk 6 to 7 of dosing and, thereafter, were maintained at a higher level in the infected animals. There were no worm eggs detectable in the feces of the control animals at any stage.
Whole-Body Leucine Kinetics
The relationships between whole-body leucine flux (WBF) and feed intake were similar in infected and control lambs throughout the experiment (Figure 1) .
Rates of blood flow across the gastrointestinal tract, leucine sequestration by gastrointestinal tract tissues, oxidative losses during gastrointestinal tract protein turnover, and the net fluxes from the gastrointestinal tract all responded to feed intake in the same linear fashion, as indicated in Figure 1 . However, the stage of infection influences the individual relationship. The linear regressions obtained for each variable vs intake in the control sheep and in those infected during the three measurement periods are presented in Table 2 . These individual relationships were then used to calculate mean values for each variable in control and infected animals at an adjusted mean intake (940 g/d). These values and the statistical assessment of differences between control and infected animals at the different stages of the experiment are given in Table 3 .
Gastrointestinal Tract Leucine Kinetics
Mesenteric and Portal Blood Flows. Infection increased blood flow to both the whole gastrointestinal tract (portal) and small intestine (mesenteric) during wk 5 to 7 and 11 to 13 of dosing with larvae. At the adjusted mean intake (940 g/d), total blood flow to the gastrointestinal tract (PDV) was increased by 23 and 28% during wk 5 to 7 and 11 to 13 of dosing, respectively. Approximately one-third of this (33 to 39%) was to the small intestine (MDV). By wk 18 to 20 of dosing, differences between infected and control animals had reduced significantly; however, PDV blood flows were still higher (P < .05) than those in the control animals. Figure 1 . Relationships between intake and whole-body flux of leucine, calculated from arterial enrichment of tracer infused into jugular vein, in control (noninfected) lambs (᭹) and lambs infected with T. colubriformis during wk 5 to 7 (᭺), 11 to 13 (ᮀ) and 18 to 20 (᭝) of dosing. The mean values predicted at an adjusted mean intake of 940 g/d from treatments and periods are given in Table 3 .
Sequestration of Leucine by GI Tract Tissues and Secretions (i) from arterial blood. Proportional extraction of arte-
rial leucine tracer across the PDV was higher (7 to 13%; P < .001) in the infected sheep (Table 4) . Extraction of tracer across the MDV was only 68% of the extraction across the PDV in the control sheep, but in the infected sheep the MDV extraction increased by 33% and, as a result the MDV extraction in infected sheep, was 78 to 84% of the PDV rates. When coupled with the increased blood flows, this translated into a substantial increase (23%; P < .001) in the rate of leucine sequestration by the whole gastrointestinal tract (Table 3) . Of this, 55 to 60% could be accounted for across the MDV. By wk 18 to 20 of dosing, these increases had reduced considerably, and, at that stage, PDV values were not significantly different from those of control animals.
(ii) from digesta during absorption. The derived rates of sequestration of luminally derived leucine during "first pass" absorptive metabolism increased (P < .05) during wk 5 to 7 and 11 to 13 of dosing, with indication of a reduction in this difference by wk 18 to 20 of dosing (Table 3) .
(iii) total gastrointestinal tract sequestration of leucine.
Collectively, arterial and luminal sequestration by the whole gastrointestinal tract (PDV) tissues was increased by 24% (86 and 88 vs 69 mmol/d; P < .05) during wk 5 to 7 and 11 to 13 of dosing. The proportion of this total sequestration, that was from arterial leucine was similar in infected and control animals (.86 for control vs .88 and .84 for the infected animals during wk 5 to 7 and 11 to 13 of dosing, respectively). However, sequestration by MDV tissues from arterial and luminal sources represented only 26% of whole gastrointestinal tract (PDV) sequestration in control animals but 32 and 38% in infected animals during wk 5 to 7 and 11 to 13 of dosing, respectively.
Oxidation of Leucine During Gastrointestinal Tract Metabolism
(i) from arterial precursors. Infection increased the rates of leucine oxidation across the PDV (Table 3) . At the adjusted mean intake (940 g/d), the values for infected animals during wk 5 to 7 and 11 to 13 of dosing were 24 and 38%, respectively, higher than for noninfected animals. Almost all of this increased oxidation occurred in tissues drained by the mesenteric arcade (Table 3) .
(ii) from luminal precursors. Rates of oxidative losses of digesta-derived leucine during "first pass" metabolism were extremely low (Table 3) . In control animals, oxidative losses represented < 1.5% of the sequestrated leucine during "first pass" absorptive metabolism. However, during infection the rates increased by 60% during wk 5 to 7 and by 250% during wk 11 to 13. Values obtained during wk 18 to 20 of dosing were still 180% higher than in the control animals. Even so, the highest oxidative loss, occurring during wk 11 to 13 of dosing, represented only 3% of the sequestrated "first pass" leucine and only 6% of the total oxidation by MDV (small intestine) tissues (i.e., from both arterial and luminal precursor leucine).
(iii) total oxidative losses across gastrointestinal tract.
Collectively, oxidative loss of leucine across the PDV increased by 24, 41 and 22% during wk 5 to 7, 11 to 13, and 18 to 20 of dosing, respectively (i.e., 9.4 vs 11.7, 13.3, and 11.5 mmol/d). These increases were mainly a reflection of the increased leucine metabolism by these tissues; there was little change in the fraction of total leucine sequestration that was oxidized (control 14% vs 14, 15, and 16% in wk 5 to 7, 11 to 13, and 18 to 20 of dosing, respectively). The increased oxidation was mainly confined to the MDV regions of the tract and to arterial leucine precursor. Thus, when total gastrointestinal tract oxidation increased by 2.2, 3.6, and 1.9 mmol/d during the three periods of infection, the calculated increases in MDV oxidation were 2.9, 3.4, and .7 Table 3 . Whole-body flux of leucine, portal and mesenteric blood flow, sequestration of leucine by the gastrointestinal tract (PDV) and small intestinal (MDV) tissues from arterial blood precursors and the luminal sequestration of digesta-derived leucine during "first pass" metabolism, oxidation of leucine sequestrated from arterial blood precursors and the luminal oxidation of leucine, and the rates of leucine availability for other tissues (net PDV flux) in control (noninfected) lambs and the lambs infected with T. colubriformis during wk 5 to 7, 11 to 13, and 18 to 20 of dosing Statistical significance: *P ≤ .05; **P ≤ .01; ***P ≤ .001; NS, not significant. mmol/d, respectively. Less than 10% of this increased oxidation resulted from absorptive metabolism of luminal leucine precursor.
Leucine Available for Other Tissues
The infection reduced (P < .001) the rates (mmol/d) of leucine available for other tissues (net PDV flux; see Table 3 ). At the adjusted mean intake (940 g/d), the net PDV fluxes of leucine in infected sheep during wk 5 to 7, 11 to 13, and 18 to 20 of dosing were 29, 32, and 20%, respectively, lower than in control sheep.
Discussion
Subclinical Model
Previous studies (Poppi et al., 1986; Kimambo et al., 1988) have linked the reduced N retention and live Table 4 . Fractional extraction of arterial leucine tracer across the gastrointestinal tract (PDV) and small intestinal (MDV) tissues in the control (noninfected) lambs and the lambs infected with T. colubriformis during wk 5 to 7, 11 to 13, and 18 to 20 of dosing Statistical significance: **P ≤ .01; ***P ≤ .001; NS, not significant. weight gain of animals subjected to subclinical T. colubriformis infection with enhanced flow of ileal digesta N, assumed to arise from exaggerated loss of unresorbed endogenous N secretions. However, the present study is thought to be the first attempt to quantify the effects of such infection on gastrointestinal tract amino acid (AA) use and oxidation in farm animals.
The etiology of the subclinical infection encompasses a number of consecutive phases. For the first 3 to 4 wk of daily dosing with larvae, there is little visible sign of any nutritional penalty, or indeed of a subclinical infection. Fecal eggs begin to appear by wk 3 to 4, and the animals experience varying degrees of inappetance and reduced live weight gain from wk 5 to 15 (see Poppi et al., 1986; Kimambo et al., 1988) . A rise in blood eosinophil concentrations indicates the development of an immune response to the larval challenge and the presence of developing and adult stages by wk 5 to 7. These peak at wk 11 to 13, by which stage the animals are developing considerable immune response to the challenge. Beyond wk 15 of dosing, the animals seem to slowly return to normal, and weight gain is returned to levels similar to those of pair-fed controls (Kimambo et al., 1988) . In the present study, measurements of gastrointestinal tract leucine turnover were taken on three occasions to coincide with the early stage of the initial infection (wk 5 to 7 of dosing), the stage when animals have developed immunological resistance to incoming larvae (wk 11 to 13 of dosing), and a later stage of immune competence when animals are well on their way to full recovery (wk 18 to 20 of dosing).
One well-established aspect of T. colubriformis infection is a variable (animal-to-animal) degree of anorexia associated with both the initial infection and the development of the immune response. This reduction in intake has been identified as an important contributor to the reduced performance of infected animals (Symons and Hennessy, 1981; Kimambo et al., 1988; Sykes, 1994) , although little is known about the mechanisms involved (Coop and Holmes, 1996) . In this study, daily intakes were reduced by up to 30% during wk 5 to 7 of dosing and up to 50% during wk 11 to 13 of dosing in individual animals, yet some did not experience any inappetance. The experimental design purposely included measurements from noninfected animals given a range of intakes, so that feed intake did not confound the statistical assessment of differences between infected and noninfected animals.
Tracers
Our previous studies have employed mainly mixed U- ]leucine, were used simultaneously to trace the use of arterial blood leucine and digesta-derived luminal leucine, having ascertained in preliminary studies that when both tracers were infused into the jugular vein their rates of extraction by gastrointestinal tract tissues were identical (data not shown). Because the effect of infection on AA oxidation was considered to be important to the pathophysiology of the condition, we decided to perform two separate dual infusions during each experimental period; the [ 13 C]leucine was introduced separately into both the blood and lumen pools in order to derive (collectively) the total gastrointestinal tract oxidative losses of leucine.
Whole-Body Kinetics
Estimates of whole-body leucine and protein flux reported in Figure 1 and Table 3 are based on the irreversible loss of tracer from the arterial blood pool. Although arterial blood H 13 CO 3 enrichments were measured, no estimate of CO 2 entry rate was determined, and so it is not possible to convert these values into rates of whole-body protein synthesis. Nevertheless, the relationships between WBF and intake given in Figure 1 reflect previous studies with pigs (Reeds et al., 1980) , steers (Lobley et al., 1987) , and sheep (Harris et al., 1992; MacRae et al., 1997; Neutze et al., 1997) . The fact that the infection did not affect the whole-body flux was perhaps surprising in view of the changes that occurred across the gastrointestinal tract, but it is consistent with earlier reports that subclinical T. colubriformis infection does not alter the relationship between metabolizable energy intake and whole-body energy expenditure (MacRae et al., 1982) .
Gastrointestinal Tract Leucine Kinetics
Rates of leucine sequestration across the gastrointestinal tract (PDV) of the noninfected animals in this study (Table 3) were similar to those reported previously for 35-kg lambs on a lucerne pelleted diet (i.e., at 800 g intake, 57 mmol/d in the present study compared to 55 mmol/d on the lucerne diet; MacRae et al., 1997) . However, in animals challenged with intestinal parasites (wk 5 to 7 and 11 to 13 of dosing) this sequestration increased by 25% in the case of the arterial precursors. Perhaps not surprisingly, in view of the fact that T. colubriformis infects mainly the upper regions (first third) of the small intestine, two-thirds of this increase occurred across the MDV regions (8 to 9 mmol/ d from arterial and 3 to 4 mmol/d from luminal precursors).
Infection also increased blood flow to the gastrointestinal tract, but whether these changes in blood flow reflected an overall increase in cardiac output during this period or a repartitioning of cardiac output to the gastrointestinal tract, at the expense of other metabolic tissues, is not known. However, data from other studies (Symons and Jones, 1975; Jones and Symons, 1982) indicate that the rates of protein synthesis in other tissues (e.g., muscle, skin/wool) decrease over these phases of the etiology of T. colubriformis infection.
The present data extend earlier findings in terms of precursor AA for intestinal tissue metabolism. In the noninfected animals, sequestration of leucine by MDV tissues (from arterial + luminal sources) accounted for 26% of total gastrointestinal tract (PDV) sequestration, this value increasing to 31 and 37% during wk 5 to 7 and 11 to 13 of dosing in the infected animals. In the noninfected animals, the MDV tissues used luminalderived and arterial precursor leucine in broadly similar proportions (55 and 45%, respectively), but, where infection increased MDV protein turnover, the extra AA was derived mainly from arterial sources, reducing the luminal contribution to only 40 to 45% of total precursor. These estimates of the proportional use of luminal leucine are much lower than values reported by Neutze et al. (1997) , who found that 70% of MDV precursor phenylalanine was derived from luminal sources. However, phenylalanine does seem to be atypical of most other essential AA when used to trace gastrointestinal tract AA sequestration. In our previous studies (MacRae et al., 1997) , when AA sequestration was determined across the PDV by infusing a mixed [ 13 C]-labeled AA tracer into both jugular and jejunal sites, the proportion of precursor phenylalanine derived from the luminal tracer was 52%, whereas corresponding values obtained using 13 C-labeled leucine, valine, lysine, threonine, isoleucine, and histidine ranged from 13 to 25%. The reason for these differences is not yet known. Separate studies have indicated that the mammary gland seems to take up appreciable quantities of peptide-bound plasma phenylalanine as a substrate for protein synthesis (Backwell et al., 1996) . If intestinal tissues are also utilizing plasma phenylalanine peptide, this would be undetected when using the free phenylalanine tracer, and this might contribute to the lower proportional use of arterial free phenylalanine.
Although the synthesis of proteins for gastrointestinal tract tissues and secretions represents a substantial energy demand, the detrimental aspects of this turnover relative to the nitrogen economy of the animal lie in the net losses of metabolic nitrogen as a consequence of oxidation and the onward passage of unresorbed endogenous secretions. Earlier studies (Poppi et al., 1986; Kimambo et al., 1988) indicating enhanced passage of digesta nitrogen leaving the small intestine of infected animals have been discussed already. The present study indicates that there is also increased AA (leucine) oxidation in the gastrointestinal tract tissues, this being a direct result of the increased leucine sequestration. On the basis that the leucine content of tissue protein in sheep is approximately 7% , the extra 3 to 3.5 mmol/d of gastrointestinal tract leucine oxidation during wk 5 to 7 and 11 to 13 of infection equates to another 1 g/d of metabolic N not available for protein deposition.
As yet, there are relatively few data on rates of amino acid oxidation across the PDV of farm animals. In a previous study (MacRae et al., 1997) , net balances of 13 CO 2 during intravascular and intraluminal infusion of [ 13 C]leucine indicated that 16 to 17% of blood precursor and 5 to 6% of luminal precursor leucine was oxidized during gastrointestinal tract protein turnover in sheep given lucerne pellets. Recent work with dairy cows (Lapierre et al., 1997) indicated that the fractional oxidation of arterial precursor leucine during gastrointestinal tract metabolism ranges from 12 to 21%. In the present study, 13 to 15% of the arterial precursor leucine was oxidized. When gastrointestinal tract oxidation increased in the infected sheep, this mainly reflected the increase in protein turnover; there was little change in the fractional rate of leucine oxidation.
The present study also confirms previous findings (MacRae et al., 1997) that sequestration of luminally derived AA and oxidation of this precursor during first pass or absorptive metabolism is only a minor component of total gastrointestinal tract AA utilization. This is contrary to a recent report of substantial (34%) AA utilization by intestinal tissues during first pass metabolism in pigs (Stoll et al., 1998) ; at least part of this discrepancy may relate to the different models developed for the calculation of AA utilization during first pass metabolism. When calculating the net tracer recovery at the portal vein during jejunal infusion (Eq.
[4]) and the first pass oxidation of AA (Eq. [6]), a major factor that needs to be accounted for is the utilization of (arterial) recirculating tracer. Thus, for example, in the control animals, for which the net recovery of tracer at the portal vein (calculated from Eq. [4]) was 88%, if the sequestration of tracer during arterial recirculation (causing a negative arteriovenous difference across the tissue bed prior to the addition of "absorbed" tracer) is not taken into account, the apparent recovery of tracer at the portal is reduced to 63%, a value more consistent with the 66% recovery by Stoll et al. (1998) . Similarly, the net 13 CO 2 flux across the PDV during the intraluminal infusion of [ 13 C]leucine indicates substantial oxidation of amino acids, but the majority of this can be accounted for from oxidation of the sequestrated recirculated (arterial) tracer. The lack of accounting for this recirculation factor may be less problematical in nonruminant animals, particularly if given highly digestible diets and hindgut fermentation is minimal, but, in ruminants, in which > 80% of AA precursor for gastrointestinal tract protein turnover is derived from arterial blood (MacRae et al., 1997) , this can lead to misleading information.
Availability of Amino Acids for Other Tissues
One consequence of the increased leucine sequestration by PDV tissues of infected animals was a reduction in the net flux of leucine across these tissues. A reduction in the availability of absorbed AA for peripheral tissue metabolism is consistent with reduced rates of protein synthesis in muscle and wool (Symons and Jones, 1975; Jones and Symons, 1982) and reduced N retention (Poppi et al., 1986; Kimambo et al., 1988) during this period of the infection. It perhaps also explained the beneficial effects of strategic supplementation with high-quality proteins during this stage to offset the degree of infection and stimulate the immune
